Brokers Offer Predictions for ABOS FY2025 Earnings

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) - Cantor Fitzgerald issued their FY2025 EPS estimates for Acumen Pharmaceuticals in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos expects that the company will post earnings per share of ($1.97) for the year. The consensus estimate for Acumen Pharmaceuticals' current full-year earnings is ($1.56) per share.

Separately, HC Wainwright reiterated a "buy" rating and set a $15.00 target price on shares of Acumen Pharmaceuticals in a research report on Wednesday, November 13th.

Acumen Pharmaceuticals Price Performance

NASDAQ:ABOS traded down $0.02 during trading hours on Thursday, reaching $1.73. 335,357 shares of the company were exchanged, compared to its average volume of 378,633. The business has a 50 day moving average of $1.98 and a 200 day moving average of $2.46. Acumen Pharmaceuticals has a 1-year low of $1.53 and a 1-year high of $5.09. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.43 and a quick ratio of 10.43. The company has a market capitalization of $103.94 million, a P/E ratio of -1.25 and a beta of 0.02.

Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.14). During the same period in the prior year, the company earned ($0.24) EPS.

Insider Transactions at Acumen Pharmaceuticals

In other Acumen Pharmaceuticals news, CEO Daniel Joseph Oconnell sold 47,778 shares of Acumen Pharmaceuticals stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $1.84, for a total value of $87,911.52. Following the transaction, the chief executive officer now owns 454,707 shares in the company, valued at $836,660.88. The trade was a 9.51 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In the last 90 days, insiders sold 98,260 shares of company stock valued at $176,430. Company insiders own 7.10% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ABOS. Franklin Resources Inc. increased its position in Acumen Pharmaceuticals by 5.4% during the 3rd quarter. Franklin Resources Inc. now owns 3,549,069 shares of the company's stock worth $8,340,000 after purchasing an additional 181,451 shares in the last quarter. FMR LLC grew its stake in shares of Acumen Pharmaceuticals by 0.3% during the third quarter. FMR LLC now owns 2,028,117 shares of the company's stock worth $5,030,000 after buying an additional 6,014 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Acumen Pharmaceuticals by 6.5% during the third quarter. Geode Capital Management LLC now owns 864,528 shares of the company's stock worth $2,144,000 after buying an additional 52,395 shares in the last quarter. State Street Corp lifted its stake in shares of Acumen Pharmaceuticals by 18.3% in the 3rd quarter. State Street Corp now owns 516,406 shares of the company's stock valued at $1,281,000 after acquiring an additional 79,841 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in shares of Acumen Pharmaceuticals during the 2nd quarter valued at $818,000. Institutional investors own 71.01% of the company's stock.

Acumen Pharmaceuticals Company Profile

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.